Reconstruction kinetics of γδ T cells after an unrelated cord blood transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational study in adults undergoing allogeneic cord blood transplantation for hematologic diseases. The research tracks γδ T cell reconstitution over time using regular blood samples and flow cytometry to measure cell numbers, proportions, and functional subsets. The goal is to see if specific γδ T cell recovery patterns predict key clinical outcomes and identify biomarkers to guide future immunotherapies. The study does not involve an intervention beyond the transplant itself and observational monitoring. Findings could inform strategies to optimize immune recovery after cord blood transplantation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1: Patients undergo their first unrelated cord blood transplantation (UCBT) at our institution.

  2: Diagnosis of a hematologic malignancy or disorder eligible for UCBT (e.g., acute leukemia, myelodysplastic syndrome, severe aplastic anemia)

  3: Willing and able to provide written informed consent.

  4: No restrictions on gender, age, or race.

Exclusion Criteria:

* Participation in an interventional clinical trial investigating prophylactic donor-derived cell infusion (e.g., DLI, MSC) during the study period.

Where it's running

• the First Affiliated Hospital of University of Science and Technology of China
  Hefei, Anhui, China Recruiting

Study contacts

• Principal investigator: Xiao yu Zhu, ph.D — The First Affiliated Hospital of University of Science and Technology of China
• Study coordinator: Xiao yu Zhu, ph.D
• Email: xiaoyuz@ustc.edu.cn
• Phone: 15255456091

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HSCT outcomes in children at Ramathibodi Hospital

  This study tests how hematopoietic stem cell transplantation works in pediatric patients with blood diseases, cancers, and other conditions at Ramathibodi Hospital.

  Recruiting Mahidol University · Ratchathewi, Bangkok · NCT07857746

• Clonal haematopoiesis assessment and long-term monitoring for prevention and care

  This project will follow people aged 55 and older who have clonal haematopoiesis or unexplained low blood counts to see how their blood changes over time and whether they develop heart disease or blood cancers.

  Recruiting Clinical Hub for Interventional Research (CHOIR) · Canberra, Australian Capital Territory · NCT07313059

• KLN-1010 gene therapy for relapsed or refractory multiple myeloma

  This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 11 sites Phase 1 Kelonia Therapeutics, Inc. · Duarte, California and 10 other locations · NCT07075185

• Early tacrolimus in HLA-mismatched haploidentical blood stem-cell transplant with post-transplant cyclophosphamide

  This trial tests whether starting tacrolimus earlier, together with post-transplant cyclophosphamide and mycophenolate, can reduce cytokine release syndrome in people receiving HLA-mismatched haploidentical peripheral blood stem-cell transplants.

  Recruiting Phase 2 Northside Hospital, Inc. · Atlanta, Georgia · NCT06828796

• Lusutrombopag to help platelet recovery after allogeneic stem cell transplant

  This will test whether the oral drug lusutrombopag helps restore platelet counts in adults after HLA haploidentical allogeneic stem cell transplantation for blood disorders.

  Recruiting The General Hospital of Western Theater Command · Chengdu · NCT07483385

• Second or greater stem cell transplant using reduced intensity conditioning

  This study is testing a gentler approach to give a second or more stem cell transplant to patients with blood disorders who didn't get enough benefit from their first transplant to see if it helps them recover better.

  Recruiting Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT01666080

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.